BPC-157 20mg Pen

This listing is the liquid, pre-filled version of BPC-157 in the ProPeptide range. Where the vial format arrives as freeze-dried powder, the pen arrives already in solution: 20mg of peptide in a 3mL aqueous fill, sealed inside a pen-style device at the point of manufacture.

The molecule itself is the same in both formats. BPC-157 is a synthetic chain of 15 amino acids, GEPPPGKPADDAGLV, modelled on a fragment of a larger protein that a Zagreb group reported from human gastric juice in 1993. Most of the published work still comes from that laboratory.

What the published work mostly contains is rat and cell data. FDA's July 2026 briefing on BPC-157 counted only five human studies: two placebo-controlled enema studies from 2002 to 2005 that were reported only as conference abstracts, and three uncontrolled pilot reports from a single Florida physician. None of them has shown efficacy, and no country has approved BPC-157 as a medicine.

This pen is sold to laboratories as a reference material and nothing more. For research use only. Not for human or veterinary use.

Remy Research carries ProPeptide BPC-157 in two formats. The sequence is identical; the physical form and fill are not.

Already in solution

The pen is filled as an aqueous solution before it is sealed, so there is no powder-handling stage in your lab and no diluent to source. The trade-off is that the solvent, concentration and fill volume are fixed by the manufacturer rather than chosen by the researcher.

Twice the peptide of the vial

Each pen carries a nominal 20mg of BPC-157, double the 10mg in the freeze-dried vial. Bear in mind that a label mass usually counts the whole fill of peptide salt and residual water, not net peptide alone.

Stability is the vial's strength

Peptides generally keep longer as dry powder than in liquid. If a project needs long storage, or needs to control its own solvent and concentration, the lyophilised vial is usually the better fit. The reasons are set out in our peptide stability and storage guide.

What is, and is not, documented

ProPeptide specifies its BPC-157 products at ≥99% purity by HPLC. That is a line specification, not a batch result: no third-party lab report for any BPC-157 pen batch is public so far. Every independent report we do hold is listed in the lab results library; for the fields a trustworthy certificate carries, read the COA and HPLC purity guide.

Cold-chain delivery

We deliver to all seven emirates, and the pen stays between 2 and 8°C in cold-chain packaging throughout. Inside Dubai, anything ordered ahead of 4 PM reaches you the same day, usually within about four hours. Cut-offs for the other emirates, and charges, are on the delivery page.

Researchers have not pinned BPC-157 to a single receptor. The literature instead describes several overlapping pathways, nearly all of them observed in rodents or cultured cells. Treat each one below as a working hypothesis rather than an established effect in people.

VEGFR2 and new capillaries

In endothelial cell experiments published in 2017, BPC-157 raised the expression and activation of VEGFR2, a receptor that drives capillary growth, and blood flow returned sooner in rodent ischaemia models.

Nitric oxide balance

Work from the Zagreb group reports that BPC-157 counters experimentally disturbed nitric oxide signalling in rodents, including the effects of blocking the enzyme eNOS. Because the effect is lost when nitric oxide production is fully shut down, the authors argue that this pathway is part of how the peptide acts.

Tendon fibroblasts

In a 2003 rat study, a surgically divided Achilles tendon healed faster in animals given BPC-157. Cell work in 2011 tied the peptide to better survival and outgrowth of tendon fibroblasts, linked to phosphorylation of focal adhesion kinase and paxillin.

Stomach and gut lining

The earliest experiments, which gave the compound its name, reported fewer stomach and duodenal lesions in rats exposed to alcohol and other irritants.

What this does not show

The one randomised efficacy study, an ulcerative colitis enema trial, was judged by FDA in 2026 to be too thinly reported to support effectiveness. A sham-controlled US trial is planned to start in 2027. Until controlled human data exist, these mechanisms describe animal and cell findings only. The BPC-157 research review gives full citations, and BPC-157 vs TB-500 compares it with a peptide often studied alongside it.